Liposomal formulation of amphotericin B for the treatment of mucosal leishmaniasis in HIV-negative patients

被引：27

作者：

Rocio, Carolina ^{[1
]}

Amato, Valdir Sabbaga ^{[1
]}

Camargo, Raphael A. ^{[1
]}

Tuon, Felipe F. ^{[2
]}

Nicodemo, Antonio Carlos ^{[1
]}

机构：

[1] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil

[2] Univ Fed Parana, Clin Univ Hosp, Div Infect Dis, BR-80060000 Curitiba, PR, Brazil

来源：

TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE | 2014年 / 108卷 / 03期

关键词：

Amphotericin B; Leishmania treatment; Leishmaniasis;

D O I：

10.1093/trstmh/tru011

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Background: Studies assessing the efficacy of liposomal amphotericin B (LAB) in the treatment of patients with mucosal leishmaniasis (ML) are very scarce in the literature and an optimal dose regimen has not yet been defined. Methods: We performed a retrospective and descriptive analysis from records of 16 patients with ML treated with LAB. The mean daily dose of LAB was 2.5 mg/kg/day. Results: Healing of the lesion was observed in 14 (88%) of the 16 patients. The mean cumulative doses, excluding the two treatment failures, were 2265 mg and 33 mg/kg. Conclusion: Liposomal amphotericin B in the cumulative dose of 30 to 35 mg/kg was able to achieve 100% effectiveness.

引用

页码：176 / 178

页数：3

共 50 条

[21] VISCERAL LEISHMANIASIS FOLLOWING TREATMENT WITH LIPOSOMAL AMPHOTERICIN-B
MCBRIDE, M
LINNEY, M
CLAYDON, EJ
WEBER, J
CLINICAL INFECTIOUS DISEASES, 1994, 19 (02) : 362 - 362
[22] Disseminated tegumentary leishmaniasis refractory to liposomal amphotericin B treatment
Borges, Ana Flavia
Molina, Juliana D'Andrea
Milanez Morgado de Abreu, Marilda Aparecida
REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL, 2021, 54
[23] Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009
Rosenthal, E.
Delaunay, P.
Jeandel, P. -Y.
Haas, H.
Pomares-Estran, C.
Marty, P.
MEDECINE ET MALADIES INFECTIEUSES, 2009, 39 (10): : 741 - 744
[24] Immunosuppressants and amphotericin B liposomalVisceral leishmaniasis and amphotericin B liposomal treatment failure: case report
Reactions Weekly, 2017, 1645 (1) : 159 - 159
[25] Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients
Molina, I.
Falco, V.
Crespo, M.
Riera, C.
Ribera, E.
Curran, A.
Carrio, J.
Diaz, M.
del Saz, S. Villar
Fisa, R.
Lopez-Chejade, P.
Ocana, I.
Pahissa, A.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 60 (04) : 837 - 842
[26] LIPOSOMAL AMPHOTERICIN-B FOR LEISHMANIASIS TREATMENT OF AIDS PATIENTS UNRESPONSIVE TO ANTIMONIUM COMPOUNDS
LAZANAS, MC
TSEKES, GA
PAPANDREOU, S
HARHALAKIS, N
SCANDALI, A
NIKIFORAKIS, E
SAROGLOU, G
AIDS, 1993, 7 (07) : 1018 - 1019
[27] Successful response to liposomal amphotericin B in mucosal leishmaniasis in glans resistant to intralesional pentavalent
Aguayo-Carreras, Paula
Cuenca-Barrales, Carlos
Perez-Lopez, Israel
Ruiz-Villaverde, Ricardo
Tercedor-Sanchez, Jesus
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2019, 58 (07) : E137 - E138
[28] Short Report: Can We Use a Lower Dose of Liposomal Amphotericin B for the Treatment of Mucosal American Leishmaniasis?
Amato, Valdir S.
Tuon, Felipe F.
Camargo, Raphael A.
Souza, Regina M.
Santos, Carolina R.
Nicodemo, Antonio C.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2011, 85 (05): : 818 - 819
[29] Treatment of mucosal leishmaniasis with amphotericin B lipid complex (ABLC)
Tuon, Felipe Francisco
Santos, Carolina Rocio
Cieslinski, Juliette
de Souza, Regina Maia
Imamura, Rui
Amato, Valdir Sabbaga
REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO, 2018, 60
[30] Liposomal Amphotericin B and Leishmaniasis: Dose and Response
Sundar, Shyam
Chakravarty, Jaya
JOURNAL OF GLOBAL INFECTIOUS DISEASES, 2010, 2 (02) : 159 - 166

← 1 2 3 4 5 →